The role of lipids in transplant vascular disease

Laboratory Investigation

Volumn 78, Issue 10, 1998, Pages 1187-1201

  McDonald, Paul Christopher ^a   Kenyon, Jennifer Anne ^a   McManus, Bruce Maxwell ^a  

^a ST PAUL S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; APOLIPOPROTEIN; AZATHIOPRINE; CHOLESTEROL; CHOLESTEROL ESTERASE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLOSPORIN; FATTY ACID; FIBRINOGEN; FLUINDOSTATIN; GROWTH FACTOR; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; INTERMEDIATE DENSITY LIPOPROTEIN; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; MEVINOLIN; PHOSPHOLIPID; PRAVASTATIN; PREDNISONE; PROTEOGLYCAN; SIMVASTATIN; TACROLIMUS; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANGIOGRAPHY; DRUG SAFETY; DYSLIPIDEMIA; GENE EXPRESSION; GRAFT REJECTION; HUMAN; HYPERLIPIDEMIA; INTRAVASCULAR ULTRASOUND; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; VASCULAR DISEASE;

ANIMALS; HUMANS; LIPIDS; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS; VASCULAR DISEASES;

EID: 0031754239     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (122)

1. Adams DH and Karnovsky MJ (1989). Hypercholesterolemia does not exacerbate arterial intimai thickening in chronically rejecting rat cardiac allografts. Transplant Proc 21:437-439.
2. Alonso DR, Starek PK, and Minick CR (1977). Studies on the pathogenesis of atheroarteriosclerosis induced in rabbit cardiac allografts by the synergy of graft rejection and hypercholesterolemia. Am J Pathol 87:415-442.
3. Amenta JS and Waters LL (1960). The precipitation of serum lipoproteins by mucopolysaccharides extracted from aortic tissue. Yale J Biol Med 33:112-121.
4. Andersen HO, Holm P, Nordestgaard BG, Hansen BF, Kjeldsen K, Elinder LS, and Stender S (1995). Effect of the antioxidant probucol on transplant arteriosclerosis in aorta-allografted rabbits. J Mol Cell Cardiol 27:1561-1571.
5. Andersen HO, Madsen G, Nordestgaard BG, Hansen BF, Kjeldsen K, and Stender S (1994). Cyclosporin suppresses transplant arteriosclerosis in the aorta-allografted, cholesterol-clamped rabbit: Suppression preceded by decrease in arterial lipoprotein permeability. Arterioscler Thromb 14:944-950.
6. Ballantyne CM, Bourge RC, Domalik LJ, Eisen HJ, Fishbein DP, Kubo SH, Lake KD, Radovancevic B, Taylor DO, Ventura HO, Yancy CW Jr, and Young JB (1996). Treatment of hyperlipidemia after heart transplantation and rationale for the Heart Transplant Lipid Registry. Am J Cardiol 78:532-535.
7. Ballantyne CM, Podet EJ, Patsch WP, Harati Y, Appel V, Gotto AM Jr, and Young JB (1989). Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA 262:53-56.
8. Ballantyne CM, Radovancevic B, Farmer JA, Frazier OH, Chandler L, Payton-Ross C, Cocanougher B, Jones PH, Young JB, and Gotto AM Jr (1992). Hyperlipidemia after heart transplantation: Report of a 6-year experience, with treatment recommendations. J Am Coll Cardiol 19:1315-1321.
9. Barbir M, Rose M, Kushwaha S, Akl S, Mitchell A, and Yacoub M (1991). Low-dose simvastatin for the treatment of hypercholesterolaemia in recipients of cardiac transplantation. Int J Cardiol 33:241-246.
10. Becker DM, Chamberlain B, Swank R, Hegewald MG, Girardet R, Baughman KL, Kwiterovich PO, Pearson TA, Ettinger WH, and Renlund D (1988). Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients. Am J Med 85:632-638.
11. Bieber CP, Hunt SA, Schwinn DA, Jamieson SA, Reitz BA, Oyer PE, Shumway NE, and Stinson EB (1981). Complications in long-term survivors of cardiac transplantation. Transplant Proc 13:207-211.
12. Bieber CP, Stinson EB, Shumway NE, Payne R, and Kosek J (1970). Cardiac transplantation in man: VII - Cardiac allograft pathology. Circulation 41:753-772.
13. Billingham ME (1992). Histopathology of graft coronary disease. J Heart Lung Transplant 11:S38-S44.
14. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, and Dodge HT (1990). Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323:1289-1298.
15. Brown JH, Murphy BG, Douglas AF, Short CD, Bhatnagar D, Mackness MI, Hunt LP, Doherty CC, and Durrington PN (1997). Influence of immunosuppressive therapy on lipoprotein(a) and other lipoproteins following renal transplantation. Nephron 75:277-282.
16. Busch G, Galvanek E, and Reynolds E (1971). Human renal allografts: Analysis of lesions in long-term survivors. Hum Pathol 2:253-298.
17. Camejo G (1982). The interaction of lipids and lipoproteins with the intercellular matrix of arterial tissue: Its possible role in atherogenesis. Adv Lipid Res 19:1-53.
18. Camejo G, Fager G, Rosengren B, Hurt-Camejo E, and Bondjers G (1993). Binding of low density lipoproteins by proteoglycans synthesized by proliferating and quiescent human arterial smooth muscle cells. J Biol Chem 268:14131-14137.
19. Dart A, Jerums G, Nicholson G, d'Emden M, Hamilton-Craig I, Tallis G, Best J, West M, Sullivan D, Bracs P, and Black D (1997). A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol 80:39-44.
20. East C, Alivizatos PA, Grundy SM, Jones PH, and Farmer JA (1988). Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation (letter). N Engl J Med 318:47-48.
21. Eich D, Thompson JA, Ko D, Hastillo A, Lower R, Katz S, Katz M, and Hess ML (1991). Hypercholesterolemia in long-term survivors of heart transplantation: An early marker of accelerated coronary artery disease. J Heart Lung Transplant 10:45-49.
22. Emeson EE and Shen ML (1993). Accelerated atherosclerosis in hyperlipidemic C57BL/6 mice treated with cyclosporin A. Am J Pathol 142:1906-1915.
23. Escobar A, Ventura HO, Stapleton DD, Mehra MR, Ramee SR, Collins TJ, Jain SP, Smart FW, and White CJ (1994). Cardiac allograft vasculopathy assessed by intravascular ultrasonography and nonimmunologic risk factors. Am J Cardiol 74:1042-1046.
24. Esper E, Glagov S, Karp RB, Simonsen KK, Filer SR, Scanu AM, and Sand ME (1997). Role of hypercholesterolemia in accelerated transplant coronary vasculopathy: Results of surgical therapy with partial ileal bypass in rabbits undergoing heterotopic heart transplantation. J Heart Lung Transplant 16:420-435.
25. Evanko SP, Raines EW, Ross R, Gold LI, and Wight TN (1998). Proteoglycan distribution in lesions of atherosclerosis depends on lesion severity, structural characteristics, and the proximity of platelet-derived growth factor and transforming growth factor-b. Am J Pathol 152:533-546.
26. Fabricant CG, Fabricant J, Minick CR, and Litrenta MM (1983). Herpesvirus-induced atherosclerosis in chickens. Fed Proc 42:2476-2479.
27. Fabricant CG, Hajjar DP, Minick CR, and Fabricant J (1981). Herpesvirus infection enhances cholesterol and cholesteryl ester accumulation in cultured arterial smooth muscle cells. Am J Pathol 105:176-184.
28. Fellstrom B, Dimeny E, Larsson E, Claesson K, and Tufveson G (1990). Rapidly proliferative arteriopathy in cyclosporin-induced permanently surviving rat cardiac allografts simulating chronic vascular rejection. Clin Exp Immunol 80:288-292.
29. Ferns G, Reidy M, and Ross R (1990). Vascular effects of cyclosporine A in vivo and in vitro. Am J Pathol 137:403-413.
30. Foegh ML, Khirabadi BS, Chambers E, Amamoo S, and Ramwell PW (1989). Inhibition of coronary artery transplant atherosclerosis in rabbits with angiopeptin, an octapeptide. Atherosclerosis 78:229-236.
31. Gao SZ, Alderman EL, Schroeder JS, Silverman JF, and Hunt SA (1988). Accelerated coronary vascular disease in the heart transplant patient: Coronary arteriographic findings. J Am Coll Cardiol 12:334-340.
32. Gao SZ, Schroeder JS, Alderman EL, Hunt SA, Silverman JF, Wiederhold V, and Stinson EB (1987). Clinical and laboratory correlates of accelerated coronary artery disease in the cardiac transplant patient. Circulation 76:V56-V61.
33. Goggins WC, Fisher RA, Cohen DS, Tawes JW, and Grimes MM (1996). Effect of single-dose rapamycin-based immunosuppression on the development of cardiac allograft vasculopathy. J Heart Lung Transplant 15:790-795.
34. Gould L, Rossouw J, Santanello N, Heyse J, and Furberg C (1998). Cholesterol reduction yields clinical benefit: Impact of statin trials. Circulation 97:946-952.
35. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, and Shumway NE (1989). Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 261:3561-3566.
36. Group for the SSSS (1994). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389.
37. Gulizia JM, Kandolf R, Kendall TJ, Thieszen SL, Wilson JE, Radio SJ, Costanzo MR, Winters GL, Miller LL, and McManus BM (1995). Infrequency of cytomegalovirus genome in coronary arteriopathy of human heart allografts. Am J Pathol 147:461-475.
38. Hajjar DP, Pomerantz KB, Falcone DJ, Weksler BB, and Grant AJ (1987). Herpes simplex virus infection in human arterial cells: implications in arteriosclerosis. J Clin Invest 80:1317-1321.
39. Harris KPG, Russell GI, Parvin SD, Veitch PS, and Walls J (1986). Alterations in lipid and carbohydrate metabolism attributable to cyclosporin A in renal transplant recipients. Br Med J (Clin Res Ed) 292:16.
40. Hauptman PJ, Davis SF, Miller L, and Yeung AC (1995). The role of nonimmune risk factors in the development and progression of graft arteriosclerosis: Preliminary insights from a multicenter intravascular ultrasound study. J Heart Lung Transplant 14:5238-5242.
41. Herd JA, Ballantyne CM, Farmer JA, Ferguson JJ III, Jones PH, West MS, Gould KL, and Gotto AM Jr (1997). Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 80:278-286.
42. Hess ML, Hastillo A, Mohanakumar DVM, Cowley MJ, Vetrovac G, Szentpetery S, Wolfgang TC, and Lower RR (1983). Accelerated atherosclerosis in cardiac transplantation: Role of cytotoxic B-cell antibodies and hyperlipidemia. Circulation 68(Suppl 2):IL94-IL101.
43. Hohage H, Arlt M, Bruckner D, Dietl KH, Zidek W, and Spieker S (1997). Effects of cyclosporin A and FK 506 on lipid metabolism and fibrinogen in kidney transplant recipients. Clin Transplant 11:225-230.
44. Hosenpud JD, Bennett LE, Keck BM, Fiol B, and Novick RJ (1997). The Registry of the International Society for Heart and Lung Transplantation: Fourteenth official report-1997. J Heart Lung Transplant 16:691-712.
45. Hughes SE and Gruber SA (1996). New immunosuppressive drugs in organ transplantation. J Clin Pharmacol 36:1081-1092.
46. Hume DM, Merrill JP, Miller BF, and Thorn GW (1955). Experiences with renal homotransplantation in the human: Report of nine cases. J Clin Invest 31:327-382.
47. Hurt-Camejo E, Camejo G, Rosengren B, Lopez F, Ahlstrom C, Fager G, and Bondjers G (1992). Effect of arterial proteoglycans and glycosaminoglycans on low density lipoprotein oxidation and its uptake by human macrophages and arterial smooth muscle cells. Arterioscler Thromb 12:569-583.
48. Ismail NAE, Alavi MZ, and Moore S (1994). Lipoprotein-proteoglycan complexes from injured rabbit aortas accelerate lipoprotein uptake by arterial smooth muscle cells. Atherosclerosis 105:79-87.
49. Jacobsson J, Cheng L, Lyke K, Kuwahara M, Kagan E, Ramwell PW, and Foegh ML (1992). Effect of estradiol on accelerated atherosclerosis in rabbit heterotopic aortic allografts. J Heart Lung Transplant 11:1188-1193.
50. Johnson MR (1992). Transplant coronary disease: Nonimmunologic risk factors. J Heart Lung Transplant 11:S124-S132.
51. Jong MC, Dahlmans VE, Hofker MH, and Havekes LM (1997). Nascent very-low-density lipoprotein triacylglycerol hydrolysis by lipoprotein lipase is inhibited by apolipoprotein E in a dose-dependent manner. Biochem J 328:745-750.
52. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, and Havel RJ (1990). Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 264:3007-3012.
53. Katznelson S and Kobashigawa JA (1995). Dual roles of HMG-CoA reductase inhibitors in solid organ transplantation: Lipid lowering and immunosuppression. Kidney Int Suppl 52:8112-5115.
54. Kendall TJ, Wilson JE, Radio SJ, Kandolf R, Gulizia JM, Winters GL, Costanzo-Nordin MR, Malcolm GT, Thieszen SL, Miller LW, and McManus BM (1992). Cytomegalovirus and other herpesviruses: Do they have a role in the development of accelerated coronary arterial disease in human heart allografts? J Heart Lung Transplant 11:S14-S20.
55. Kobashigawa JA and Kasiske BL (1997). Hyperlipidemia in solid organ transplantation. Transplantation 63:331-338.
56. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI, Sabad A, Cogert GA, Trosian K, Hamilton MA, Moriguchi JD, Kawata N, Hage A, Drinkwater DC, and Stevenson LW (1995). Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333:621-627.
57. Kobashigawa JA, Murphy FL, Stevenson LW, Moriguchi JD, Kawata N, Kamjoo P, Brownfield E, Wilmarth J, Leonard L, Chuck C, Drinkwater D, and Laks H (1990). Low-dose lovastatin safely lowers cholesterol after cardiac transplantation. Circulation 82:281-283.
58. Kosek J, Bieber C, and Lower R (1971). Heart graft arteriosclerosis. Transplant Proc 3:512-514.
59. Kosek J, Hurley E, and Sewell D (1969). Histopathology of orthotopic canine cardiac homografts and its clinical correlation. Transplant Proc 1:311-315.
60. Koskinen PK, Lemstrom KB, and Hayry PJ (1995). How cyclosporine modifies histological and molecular events in the vascular wall during chronic rejection of rat cardiac allografts. Am J Pathol 146:972-980.
61. Lemstrom KB, Raisanen-Sokolowski AK, Hayry PJ, and Koskinen PK (1996). Triple drug immunosuppression significantly reduces aortic allograft arteriosclerosis in the rat. Arterioscler Thromb Vasc Biol 16:553-564.
62. Lin H, Ignatescu M, Wilson JE, Roberts CR, Horley KJ, Winters GL, Costanzo MR, and McManus BM. (1996a). Prominence of apolipoproteins B, (a), and E in the intimae of coronary arteries in transplanted human hearts: Geographic relationship to vessel wall proteoglycans. J Heart Lung Transplant 15:1223-1232.
63. Lin H, Wilson JE, Kendall TJ, Radio SJ, Cornhill FJ, Herderick E, Winters GL, Costanzo MR, Porter T, Thieszen SL, and McManus BM (1994). Comparable proximal and distal severity of intimal thickening and size of epicardial coronary arteries in transplant arteriopathy of human cardiac allografts. J Heart Lung Transplant 13:824-833.
64. Lin H, Wilson JE, Roberts CR, Horley KJ, Winters GL, Costanzo MR, and McManus BM. (1996b). Biglycan, decorin, and versican protein expression patterns in coronary arteriopathy of human cardiac allograft: Distinctness as compared to native atherosclerosis. J Heart Lung Transplant 15:1233-1247.
65. Malcom GT, Strong JP, and Restrepo C (1984). Atherosclerosis and lipid composition of the abdominal aorta: Comparison of autopsied New Orleans and Guatemalan men. Lab Invest 50:79-86.
66. Massy ZA and Kasiske BL (1996). Post-transplant hyperlipidemia: Mechanisms and management. J Am Soc Nephrol 7:971-977.
67. McDonald K, Rector TS, Braulin EA, Kubo SH, and Olivari MT (1989). Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus infection. Am J Cardiol 64:359-362.
68. McManus BM, Horley KJ, Wilson JE, Malcom GT, Kendall TJ, Miles RR, Winters GL, Costanzo MR, Miller LL, and Radio SJ (1995). Prominence of coronary arterial wall lipids in human heart allografts: Implications for pathogenesis of allograft arteriopathy. Am J Pathol 147:293-308.
69. McManus BM, Malcolm G, Kendall TJ, Gulizia JM, Wilson JE, Winters G, Costanzo MR, Thieszen S, and Radio SJ (1994). Lipid overload and proteoglycan expression in chronic rejection of the human transplanted heart. Clin Transplant 8:336-340.
70. Mehra MR, Ventura HO, Jain SP, Ramireddy K, Ali A, Stapleton DD, Smart FW, Ramee SR, Collins TJ, and White CJ (1997). Heterogeneity of cardiac allograft vasculopathy: Clinical insights from coronary angioscopy. J Am Coll Cardiol 29:1339-1344.
71. Mehta D, Angelini GD, and Bryan AJ (1996). Experimental models of accelerated atherosclerosis syndromes. Int J Cardiol 56:235-257.
72. Mennander A, Tiisala S, Paavonen T, Halttunen J, and Hayry P (1991). Chronic rejection of rat aortic allograft: II -Administration of cyclosporin induces accelerated allograft arteriosclerosis. Transplant Int 4:173-179.
73. Mennander A, Tikkanen MJ, Raisanen-Sokolowski A, Paavonen T, Ustinov J, and Hayry P (1993). Chronic rejection in rat aortic allografts: IV - Effect of hypercholesterolemia in allograft arteriosclerosis. J Heart Lung Transplant 12:123-132.
74. Miller L, Kobashigawa J, Valantine H, Ventura H, Hauptman P, O'Donnell J, Wiedermann J, and Yeung A (1995). The impact of cyclosporine dose and level on the development and progression of allograft coronary disease. J Heart Lung Transplant 14:5227-3234.
75. Minick CR, Fabricant CG, Fabricant J, and Litrenta MM (1979). Atheroarteriosclerosis induced by infection with a herpesvirus. Am J Pathol 96:673-706.
76. Minick CR and Murphy GE (1973). Experimental induction of atheroarteriosclerosis by the synergy of allergic injury to arteries and lipid-rich diet: II - Effect of repeatedly injected foreign protein in rabbits fed a lipid-rich, cholesterol-poor diet. Am J Pathol 73:265-300.
77. Moghadasian M, McManus B, Godin D, and Frohlich J (1997). Effects of probucol on the antioxidant system in apo E-deficient mice (abstract). Atherosclerosis 134:39.
78. Nicholson A and Hajjar D (1998). Herpesviruses in atherosclerosis and thrombosis: Etiologic agents or ubiquitous bystanders? Arterioscler Thromb Vasc Biol 18:339-348.
79. Norman DJ, Illingworth DR, Munson J, and Hosenpud J (1988). Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin (letter). N Engl J Med 318:46-47.
80. Park JW, Merz M, Braun P, and Vermeltfoort M (1996). Lipid disorder and transplant coronary artery disease in long-term survivors of heart transplantation. J Heart Lung Transplant 15:572-579.
81. Parks JS and Rudel LL (1990). Effect of fish oil on atherosclerosis and lipoprotein metabolism. Atherosclerosis 84:83-94.
82. Radio S, Wood S, Wilson J, Lin H, Winters G, and McManus B (1996). Allograft vascular disease: Comparison of heart and other grafted organs. Transplant Proc 28:496-499.
83. Raisanen-Sokolowski A, Tilly-Keisi T, Ustinov J, Mennander A, Paavonen T, Tikkanen MJ, and Hayry P (1994). Hyperlipidemia accelerates allograft arteriosclerosis (chronic rejection) in the rat. Arterioscler Thromb 14:2032-2042.
84. Renlund DG, Bristow MR, Crandall BG, Burton NA, Doty DB, Karwande SV, Gay Jr WA, Jones KW, Hegewald MG, Lee HR, and O'Connell JB (1989). Hypercholesterolemia after cardiac transplantation: Amelioration by corticosteroid-free maintenance immunosuppression. J Heart Transplant 8:214-219.
85. Rickenbacher PR, Kemna MS, Pinto FJ, Hunt SA, Alderman EL, Schroeder JS, Stinson EB, Popp RL, Chen I, Reaven G, and Valantine HA (1996). Coronary artery intimai thickening in the transplanted heart: An in vivo intracoronary ultrasound study of immunologic and metabolic risk factors. Transplantation 61:46-53.
86. Russell PS, Chase CM, and Colvin RB (1996). Accelerated atheromatous lesions in mouse hearts transplanted to apolipoprotein-E-deficient recipients. Am J Pathol 149:91-99.
87. Schmid C, Heemann U, Azuma H, and Tilney NL (1995). Comparison of rapamycin, RS 61443, cyclosporine, and low-dose heparin as treatment for transplant vasculopathy in a rat model of chronic allograft rejection. Transplant Proc 27:438-439.
88. Schorn TF, Kliem V, Bojanovski M, Bojanovski D, Repp H, Bunzendahl H, and Frei U (1991). Impact of long-term immunosuppression with cyclosporin A on serum lipids in stable renal transplant recipients. Transplant Int 4:92-95.
89. Shi CW, Lee WS, Russell ME, Zhang D, Fletcher DL, Newell JB, and Haber E (1997). Hypercholesterolemia exacerbates transplant arteriosclerosis via increased neointimal smooth muscle cell accumulation: Studies in apolipoprotein E knock-out mice. Circulation 96:2722-2728.
90. Simmons WD, Rayhill SC, and Sollinger HW (1997). Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection. Drug Saf 17:75-92.
91. St. Goar FG, Pinto FJ, Alderman EL, Valantine HA, Schroeder JS, Gao S-Z, Stinson EB, and Popp RL (1992). Intracoronary ultrasound in cardiac transplant recipients: In vivo evidence of "angiographically silent" intimai thickening. Circulation 85:979-987.
92. Steinberg D (1979). Research related to underlying mechanisms in atherosclerosis. Circulation 60:1559-1565.
93. Steinbrecher UP (1991). Role of lipoprotein peroxidation in the pathogenesis of atherosclerosis. Clin Cardiol 14:865-867.
94. Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, and Steinberg D (1984). Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci U S A 81:3883-3887.
95. Steinbrecher UP, Zhang HF, and Lougheed M (1990). Role of oxidatively modified LDL in atherosclerosis. Free Radic Biol Med 9:155-168.
96. Tabas I (1995). The stimulation of the cholesterol esterification pathway by atherogenic lipoproteins in macrophages. Curr Opin Lipidol 6:260-268.
97. Tanaka H, Sukhova GK, and Libby P (1994). Interaction of the allogeneic state and hypercholesterolemia in arterial lesion formation in experimental cardiac allografts. Arterioscler Thromb 14:734-745.
98. Taylor DO, Thompson JA, Hastillo A, Barnhart G, Rider S, Lower RR, and Hess ML (1989). Hyperlipidemia after clinical heart transplantation. J Heart Transplant 8:209-213.
99. Thomson J (1969). Production of severe atheromata in a transplanted human heart. Lancet 2:1088-1092.
100. Tilly-Kiesi M, Raisanen-Sokolowski A, Ustinov J, Myllarniemi M, Tikkanen MJ, and Hayry P (1995). Hyperlipidemia enhances chronic rejection in experimental rat model. Transplant Proc 27:582.
101. Uretsky BF, Murali S, Reddy PS, Rabin B, Lee A, Griffith BP, Hardesty RL, Trento A, and Bahnson HT (1987). Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation 76:827-834.
102. Valantine HA (1995). Role of lipids in allograft vascular disease: A multicenter study of intimal thickening detected by intravascular ultrasound. J Heart Lung Transplant 14:S234-S237.
103. Valantine HA and Schroeder JS (1997). HMG-CoA reductase inhibitors reduce transplant coronary artery disease and mortality: Evidence for antigen-independent mechanisms. Circulation 96:1370-1373.
104. Valantine-von Kaeppler H, Hoang K, Chen Y-I, Zhang L, Ross H, Billingham M, and Reaven G (1997a). Cardiac transplant atherosclerosis is accelerated by diabetes: Interactions with cell-mediated responses and cytokine gene expression (abstract). Circulation 96:174.
105. Valantine-von Kaeppler H, Hoang K, Dai X, Poston R, Hoyt G, Reaven G, Billingham M, and Robbins R (1997b). Insulin resistance accelerates transplant atherosclerosis in the Zucker fat rat (abstract). Circulation 96:174.
106. van den Dorpel MA, Ghanem H, Rischen-Vos J, Man in't Veld AJ, Jansen H, and Weimar W (1997). Conversion from cyclosporine A to azathioprine treatment improves LDL oxidation in kidney transplant recipients. Kidney Int 51:1608-1612.
107. Vanhaecke J, Van Cleemput J, Van Lierde J, Daenen W, and De Geest H (1994). Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine. Transplantation 58:42-45.
108. Ventura HO, Mehra MR, Smart FW, and Stapleton DD (1995). Cardiac allograft vasculopathy: Current concepts. Am Heart J 129:791-799.
109. Ventura HO, White CJ, Jain SP, Smart FW, Jain A, Stapleton DD, Collins TJ, and Ramee SR (1993). Assessment of intracoronary morphology in cardiac transplant recipients by angioscopy and intravascular ultrasound. Am J Cardiol 72: 805-809.
110. Versluis DJ, Wenting GJ, Derkx FH, Schalekamp MA, Jeekel J, and Weimar W (1987). Who should be converted from cyclosporine to conventional immunosuppression in kidney transplantation, and why. Transplantation 44:387-389.
111. Virchow R (1856). Phlogose und thrombose im gefabsystem. Gesammelte Abhandlugen zur Wissenschaftlichen. Frankfurt: Meidinger Sohn, 458.
112. Wahlers T, Mugge A, Oppelt P, Heublein B, Fieguth HG, Jurmann M, and Haverich A (1994). Coronary vasculopathy following cardiac transplantation and cyclosporine immunosuppression: Preventive treatment with angiopeptin, a somatostatin analog. Transplant Proc 26:2741-2742.
113. Wahlers T, Mugge A, Oppelt P, Heublein B, Fieguth HG, Jurmann MJ, Uthoff K, Haverich A, Albes JM, Foegh M, and Borst HG (1995). Preventive treatment of coronary vasculopathy in heart transplantation by inhibition of smooth muscle cell proliferation with angiopeptin. J Heart Lung Transplant 14:143-150.
114. Wenke K, Meiser B, Thiery J, Nagel D, von Scheldt W, Steinbeck G, Seidel D, and Reichart B (1997). Simvastatin reduces graft vessel disease and mortality after heart transplantation: A four-year randomized trial. Circulation 96: 1398-1402.
115. Wenke K, Thiery J, Meiser B, Arndtz N, Seidel D, and Reichart B (1995). Therapy of hypercholesterolemia after heart transplantation with the HMG-CoA reductase inhibitor simvastatin in long-term follow-up. Z Kardiol 84:130-136.
116. Wight TN and Ross R (1975). Proteoglycans in primate arteries: I - Ultrastructural localization and distribution in the intima. J Cell Biol 67:660-674.
117. Williams KJ and Tabas I (1995). The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 15:551-561.
118. Wilson JE, Wood S, McDonald P, Kenyon J, Dong C, and McManus BM (1997). Contribution of lipids to the pathogenesis of transplant vascular sclerosis. Transpl Immunol 5:247-250.
119. Winters GL, Kendall TJ, Radio SJ, Wilson JE, Costanzo-Nordin MR, Switzer BL, Remmenga JA, and McManus BM (1990). Posttransplant obesity and hyperlipidemia: Major predictors of severity of coronary arteriopathy in failed human heart allografts. J Heart Transplant 9:364-371.
120. Yeung AC, Davis SF, Hauptman PJ, Kobashigawa JA, Miller LW, Valantine HA, Ventura HO, Wiedermann J, and Wilensky R (1995). Incidence and progression of transplant coronary artery disease over 1 year: Results of a multicenter trial with use of intravascular ultrasound. J Heart Lung Transplant 14:8215-3220.
121. Yun KL, Fann JI, Sokoloff MH, Fong LG, Sarris GE, Billingham ME, and Miller DC (1991). Dose response of fish oil versus safflower oil on graft arteriosclerosis in rabbit heterotopic cardiac allografts. Ann Surg 214:155-167.
122. Zhu BQ, Sievers RE, Isenberg WM, Smith DL, and Parmley WW (1990). Regression of atherosclerosis in cholesterol-fed rabbits: Effects of fish oil and verapamil. J Am Coll Cardiol 15:231-237.